<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00369096</url>
  </required_header>
  <id_info>
    <org_study_id>FRIAT-BEM-2005-01</org_study_id>
    <secondary_id>BEMIDEXTRINA</secondary_id>
    <secondary_id>EudraCT:2005-005695-32</secondary_id>
    <nct_id>NCT00369096</nct_id>
  </id_info>
  <brief_title>Efficacy Study of the Addition of Bemiparin to Icodextrin Solution in Peritoneal Dialysis Patients (Bemidextrina)</brief_title>
  <official_title>Randomized, Controlled and Open Study to Assess the Efficacy (Peritoneal Biocompatibility) of the Addition of Bemiparin to Icodextrin Solution in Patients in Peritoneal Dialysis With Peritoneal Transport Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Renal Iñigo Alvarez De Toledo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Infociencia S.L</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundación Renal Iñigo Alvarez De Toledo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether addition of bemiparin, once daily in
      icodextrin solution for peritoneal dialysis for 16 weeks, increases the peritoneal capacity
      for ultrafiltration and/or reduces creatinine transport in peritoneal dialysis patients
      presenting functional disorders related to ultrafiltration deficit and/or high transport.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Peritoneal dysfunction is a common complication in patients in stable treatment with
      peritoneal dialysis. This peritoneal dysfunction is defined by an elevated creatinine
      transport and lowered standardized ultrafiltration capacity. The aim of this study is to
      evaluate the efficacy of the addition of bemiparin to icodextrin solution in patients in
      peritoneal dialysis with peritoneal transport disorders. The eligible patients are randomly
      assigned to receive the icodextrin solution with bemiparin or icodextrin solution without
      bemiparin.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy: Peritoneal function defined according to the standardized ultrafiltration capacity and/or estimated peritoneal creatinine transport estimated by D/P and mass transfer coefficient during randomized treatment</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety: Incidence of peritonitis during the randomized treatment period, defined by a cell count of peritoneal effluent with more than 100 leukocytes per mm3 with 50% or more polymorphonuclear cells</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">76</enrollment>
  <condition>Peritoneal Diseases</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bemiparin 3500 IU/day</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients over 18 years old, of either sex, who have given their informed consent to
             participate in the study.

          2. Patients in stable treatment with peritoneal dialysis for more than 6 weeks who
             present peritoneal dysfunction defined by capacity for standardized ultrafiltration
             (3.86% glucose maintained in the peritoneum for 4 hours) less than 600 ml and/or
             elevated creatinine transport (defined by D/P of creatinine higher than 0.65 after 4
             hours).

          3. Patients treated with icodextrin solution for peritoneal dialysis for at least one
             month before their inclusion.

          4. Patients in whom the remaining dialyzing liquids used in their PD contain glucose and
             GDP (glucose degradation products).

        Exclusion Criteria:

          1. Peritonitis in the past 2 months.

          2. Patients with bleeding at the time of inclusion, or patients with a history of
             clinically evident bleeding episodes and/or with increased bleeding due to any other
             homeostatic alteration that contradicts anticoagulant treatment and/or in the past two
             months have presented at least one of the following situations: active hemorrhaging or
             organic lesions susceptible to bleeding (e.g. active peptic ulcer, hemorrhagic
             cerebrovascular accident, or aneurysms).

          3. Major surgery in the past month.

          4. Known hypersensitivity to low molecular weight heparin (LMWH), heparin or substances
             of porcine origin.

          5. Known hypersensitivity to icodextrin.

          6. Patients treated with systemic anticoagulation.

          7. Patients with congenital or acquired bleeding diathesis.

          8. Damage to, or surgical interventions of, the central nervous system, eyes or ears
             within the past 2 months.

          9. Acute bacterial endocarditis or slow endocarditis.

         10. Patients with a history of heparin-associated thrombocytopenia.

         11. Patients with hepatic insufficiency (with values of AST and/or ALT &gt; 5 times the
             normal value established in the reference range of the local hospital laboratory).

         12. Severe arterial hypertension (systolic blood pressure over 200 mmHg and/or diastolic
             blood pressure over 120 mmHg).

         13. Patients with inability or suspected inability to comply with treatment and/or
             complete the study.

         14. Patients who are participating in another clinical trial or have done so in the past
             30 days.

         15. Patients with a life expectancy less than 6 months.

         16. Women who are pregnant, breast-feeding or fertile women who are not using an effective
             contraceptive method.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rafael Selgas Gutierrez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario La Paz</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mª Auxiliadora Bajo Rubio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Servicio de Nefrología del Hospital Universitario La Paz (Madrid-Spain)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dra. Gloria del Peso Gilsanz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Servicio de Nefrología del Hospital Universitario La Paz (Madrid - Spain)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antonio Carlos Fernández Perpén, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Servicio de Nefrologia del Hospital Universitario La Princesa (Madrid-Spain)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mercedes L. Velo Plaza, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Servicio de Nefrologia del Hospital Universitario Príncipe de Asturias de Alcala de Henares (Madrid - Spain)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Miguel Pérez Fontán, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Servicio de Nefrologia del Hospital Juan Canalejo (La Coruña - Spain)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maite Rivera Gorrín, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Servicio de Nefrologia del Hospital Universitario Ramón y Cajal (Madrid - Spain)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>MªTeresa Tenorio Cañamas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Servicio de Nefrologia del Hospital Universitario Ramón y Cajal (Madrid - Spain)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>José Portolés Pérez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Servicio de Nefrología de la Fundación Hospital de Alcorcón (Madrid - Spain)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juan Manuel López Gómez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Servicio de Nefrologia del Hospital Gregorio Marañón (Madrid - Spain)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Josep Teixidó, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Servicio de Nefrologia del Hospital German Trias i Pujol de Badalona (Barcelona-Spain)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mercé Borras, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Servicio de Nefrologia del Hospital Arnau de Vilanova (Lleida - Spain)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cristina Pérez Melon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Servicio de Nefrología del Hospital de Orense(Galicia-Spain)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Silvia Ros Ruíz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Servicio de Nefrologia del Hospital Regional Universitario Carlos Haya (Málaga-Spain)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Teresa González Alvarez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Servicio de Nefrología del Hospital de Bellvitge (Barcelona-Spain)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jorge Bartolome, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Servicio de Nefrologia del Hospital Vall d'Hebron (Barcelona - Spain)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Esther Ponz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Servicio de Nefrología de la Corporación Sanitaria Parc Taulí (Barcelona - Spain)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pere Torguet, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Servicio de Nefrologia del Hospital Josep Trueta (Gerona - Spain)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Manel Vera i Rivera, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Servicio de Nefrologia del Hospital Clinic de Barcelona (Barcelona - Spain)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juan Carlos Alonso, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Servicio de Nefrología del Hospital Lluis Alcanyis Xátiva (Valencia - Spain)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jose Manuel Gil, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Servicio de Nefrología del Complejo Hospitalario de Jaen (Jaen - Spain)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Regional Universitario Carlos Haya</name>
      <address>
        <city>Málaga</city>
        <state>Andalucia</state>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Corporación Sanitaria Parc Tauli</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Dr. Josep Trueta</name>
      <address>
        <city>Gerona</city>
        <state>Cataluña</state>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Orense</name>
      <address>
        <city>Orense</city>
        <state>Galicia</state>
        <zip>32005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Juan Canajelo</name>
      <address>
        <city>A Coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Príncipe de Asturias</name>
      <address>
        <city>Alcala de Henares (Madrid)</city>
        <zip>28805</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital German Trias i Pujol</name>
      <address>
        <city>Badalona (Barcelona)</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Bellvitge</name>
      <address>
        <city>Barcelona</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo hospitalario de Jaen</name>
      <address>
        <city>Jaen</city>
        <zip>23007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Arnau de Vilanova</name>
      <address>
        <city>Lleida</city>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundación Hospital Alcorcón</name>
      <address>
        <city>Madrid</city>
        <zip>28922</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 28, 2006</study_first_submitted>
  <study_first_submitted_qc>August 28, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2006</study_first_posted>
  <last_update_submitted>May 13, 2010</last_update_submitted>
  <last_update_submitted_qc>May 13, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 14, 2010</last_update_posted>
  <keyword>Peritoneal Dialysis</keyword>
  <keyword>Bemiparin</keyword>
  <keyword>Icodextrin</keyword>
  <keyword>Peritoneal Transport Disorders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peritoneal Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Icodextrin</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

